Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 829-834

  Hotta, K ^a   Kiura, K ^a   Fujiwara, Y ^a   Takigawa, N ^a   Oze, I ^a   Ochi, N ^a   Tabata, M ^a   Tanimoto, M ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Lung cancer; Objective response; Overall survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ARTICLE; BRAIN RADIATION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 65549162755     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp020     Document Type: Article

References (15)

1. Hanna N, Bunn PA Jr, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
2. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
3. Chute JP, Chen T, Feigal E et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 1999; 17: 1794-1801.
4. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002; 8: 935-938.
5. Saijo N. Strategy for the development of novel anticancer drugs. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): S97-S101.
6. Stahel RA, Ginsberg R, Havemann K et al. Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer 1989; 5: 119-126.
7. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973; 4: 31-42.
8. Chu T-M, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002; 176: 35-51.
9. van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003; 39: 2114-2120.
10. Hotta K, Matsuo K, Ueoka H et al. Continued gefitinib treatment after disease stabilisation prolongs survival of patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience. Ann Oncol 2005; 16: 1817-1823.
11. Hotta K, Kiura K, Toyooka S et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2007; 2: 632-637.
12. Hotta K, Kiura K, Takigawa N et al. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group Experience. J Cancer Res Clin Oncol 2009; 135(1): 117-123.
13. Johnson KR, Ringland C, Stokes BJ et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 2006; 7: 741-746.
14. Berlin JA, Santanna J, Schmid CH et al. Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: Ecological bias rears its ugly head. Stat Med 2002; 21: 371-387.
15. Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-672.